169 related articles for article (PubMed ID: 28339027)
1. SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway.
Qian B; Yao Y; Liu C; Zhang J; Chen H; Li H
Int J Oncol; 2017 May; 50(5):1601-1611. PubMed ID: 28339027
[TBL] [Abstract][Full Text] [Related]
2. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
3. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
[TBL] [Abstract][Full Text] [Related]
4. Combined antiangiogenic and immune therapy of prostate cancer.
Huang X; Raskovalova T; Lokshin A; Krasinskas A; Devlin J; Watkins S; Wolf SF; Gorelik E
Angiogenesis; 2005; 8(1):13-23. PubMed ID: 16132614
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
Farhadi MR; Capelle HH; Erber R; Ullrich A; Vajkoczy P
J Neurosurg; 2005 Feb; 102(2):363-70. PubMed ID: 15739567
[TBL] [Abstract][Full Text] [Related]
7. Growth factor/growth factor receptor loops in autocrine growth regulation of human prostate cancer DU145 cells.
Ligęza J; Ligęza J; Klein A
Acta Biochim Pol; 2011; 58(3):391-6. PubMed ID: 21887406
[TBL] [Abstract][Full Text] [Related]
8. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
9. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
Laird AD; Christensen JG; Li G; Carver J; Smith K; Xin X; Moss KG; Louie SG; Mendel DB; Cherrington JM
FASEB J; 2002 May; 16(7):681-90. PubMed ID: 11978732
[TBL] [Abstract][Full Text] [Related]
10. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
[TBL] [Abstract][Full Text] [Related]
11. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
[TBL] [Abstract][Full Text] [Related]
12. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
13. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.
Lamoureux F; Thomas C; Crafter C; Kumano M; Zhang F; Davies BR; Gleave ME; Zoubeidi A
Clin Cancer Res; 2013 Feb; 19(4):833-44. PubMed ID: 23258740
[TBL] [Abstract][Full Text] [Related]
14. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Yang GW; Jiang JS; Lu WQ
Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
[TBL] [Abstract][Full Text] [Related]
15. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression.
Henderson V; Smith B; Burton LJ; Randle D; Morris M; Odero-Marah VA
Cell Adh Migr; 2015; 9(4):255-64. PubMed ID: 26207671
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
17. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
18. Opposite regulation of epithelial-to-mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells.
Kim CJ; Sakamoto K; Tambe Y; Inoue H
Int J Oncol; 2011 Jun; 38(6):1759-66. PubMed ID: 21468544
[TBL] [Abstract][Full Text] [Related]
19. MiR-218 impedes IL-6-induced prostate cancer cell proliferation and invasion via suppression of LGR4 expression.
Li F; Gu C; Tian F; Jia Z; Meng Z; Ding Y; Yang J
Oncol Rep; 2016 May; 35(5):2859-65. PubMed ID: 26986507
[TBL] [Abstract][Full Text] [Related]
20. The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells.
Marchiani S; Bonaccorsi L; Ferruzzi P; Crescioli C; Muratori M; Adorini L; Forti G; Maggi M; Baldi E
J Cancer Res Clin Oncol; 2006 Jun; 132(6):408-16. PubMed ID: 16485114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
